Gold prices consolidated just above the $1,800 mark as the metal entered a bullish consolidation phase, oscillating in a narrow trading band near two-and-a-half week highs. Sentiment was mixed as the US FDA approval of the Pfizer vaccine boosted risk appetite, capping gold's upside, while Delta variant concerns eased fears of a Fed tapering. Investors were also reluctant to take positions ahead of the Jackson Hole Symposium. Technical indicators signaled room for further gold gains if it can break above key hurdles like the 100-day and 200-day SMAs at $1,810-12.